Key result
In heart transplant recipients, the presence of anti-HLA antibodies was associated with the development of cardiac allograft vasculopathy at 2 years.
Why the study?
Anti-HLA antibodies are linked to complications and mortality in heart transplantation, but early non-invasive signs of myocardial dysfunction without overt antibody-mediated rejection and their prognostic impact needed identification.
Does the presence of anti-HLA antibodies correlate with early myocardial dysfunction and worse prognosis in heart transplant patients without overt rejection?
Cohort (n=113)
Does the presence of anti-HLA antibodies correlate with early myocardial dysfunction and worse prognosis in heart transplant patients without overt rejection?
Answers are grounded in this paper and cite their sources.
The presence of circulating anti-HLA antibodies in heart transplant recipients is associated with mild cardiac dysfunction and predicts the development of cardiac allograft vasculopathy even without overt rejection.
AIMS: The presence of anti-human leucocyte antigen (HLA) antibodies has been implicated in a higher incidence of complications as well as mortality rate in heart transplantation. The aim of the study was to identify through non-invasive parameters early signs of myocardial dysfunction in the presence of anti-HLA antibodies but without evidence of antibody-mediated rejection (AMR) and its possible prognostic impact. METHODS AND RESULTS: A total of 113 heart-transplanted patients without acute cellular rejection (ACR) and AMR or cardiac allograft vasculopathy (CAV) were prospectively enrolled and divided into two groups ['HLA+' (50 patients) and 'HLA-' (63 patients)], based on the presence of anti-HLA antibodies. Each patient was followed for 2 years after the enrolment, recording episodes of AMR, ACR, CAV, and mortality. Clinical characteristics were similar between the two groups. Among laboratory data, N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin values were significantly higher in the presence of anti-HLA antibodies (P < 0.001 and P = 0.003, respectively). The echocardiographic parameters that showed a statistically significant difference between the two groups were deceleration time of E wave (DecT E, P < 0.001), left ventricular global longitudinal strain (P < 0.001), tricuspid annular plane systolic excursion (P = 0.011), tricuspid S' wave (P = 0.002), and free wall right ventricular longitudinal strain (fwRVLS, P = 0.027), whereas left atrial strain did not differ significantly (P = 0.408). Univariate analysis showed that anti-HLA antibodies were associated with the development of CAV at both 1 and 2 year follow-up [odds ratio (OR) 11.90, 95% confidence interval (CI) 1.43-90.79, P = 0.022 and OR 3.37, 95% CI 1.78-9.67, P = 0.024, respectively]. Bivariate analysis demonstrated that both fwRVLS and DecT E were predictors of CAV development independently from HLA status. CONCLUSIONS: The presence of circulating anti-HLA antibodies is correlated with a mild cardiac dysfunction, even in the absence of AMR, and CAV development. Interestingly, reduced values of DecT E and fwRVLS were predictors of future development of CAV, independently from anti-HLA antibody.
No takes yet. Share an insight, caveat, or question.
Sciaccaluga et al. (2023) conducted a cohort in Heart transplantation (n=113). Anti-HLA antibodies vs. Absence of anti-HLA antibodies was evaluated on Development of cardiac allograft vasculopathy at 2 years (OR 3.37, 95% CI 1.78-9.67, p=0.024). In heart transplant recipients, the presence of anti-HLA antibodies was associated with the development of cardiac allograft vasculopathy at 2 years.
Synapse has enriched 10 related papers. Consider them for comparative context: